Cargando…
SAINT: A Phase I/Expanded Phase II Study Using Safe Amounts of Ipilimumab, Nivolumab and Trabectedin as First-Line Treatment of Advanced Soft Tissue Sarcoma
SIMPLE SUMMARY: The SAINT study is an early-stage clinical trial based on the hypothesis that immunotherapy is more effective when given earlier in the course of the disease in patients with advanced soft tissue sarcoma. It consists of two parts. Phase I aims to determine the maximum acceptable dose...
Autores principales: | Gordon, Erlinda Maria, Chawla, Sant P., Tellez, Walter Andree, Younesi, Elan, Thomas, Sonu, Chua-Alcala, Victoria S., Chomoyan, Hripsime, Valencia, Chrysler, Brigham, Don Arlen, Moradkhani, Ania, Quon, Doris, Srikureja, Amornchit, Wong, Steven G., Tseng, William, Federman, Noah |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9913367/ https://www.ncbi.nlm.nih.gov/pubmed/36765863 http://dx.doi.org/10.3390/cancers15030906 |
Ejemplares similares
-
Activity of TNT: a phase 2 study using talimogene laherparepvec, nivolumab and trabectedin for previously treated patients with advanced sarcomas (NCT# 03886311)
por: Chawla, Sant P., et al.
Publicado: (2023) -
Trabectedin for Soft Tissue Sarcoma: Current Status and Future Perspectives
por: Gordon, Erlinda M., et al.
Publicado: (2016) -
Phase I/II and Phase II Studies of Targeted Gene Delivery In Vivo: Intravenous Rexin-G for Chemotherapy-resistant Sarcoma and Osteosarcoma
por: Chawla, Sant P, et al.
Publicado: (2009) -
Advanced Phase I/II Studies of Targeted Gene Delivery In Vivo: Intravenous Rexin-G for Gemcitabine-resistant Metastatic Pancreatic Cancer
por: Chawla, Sant P, et al.
Publicado: (2009) -
Phase II study of ipilimumab and nivolumab in leptomeningeal carcinomatosis
por: Brastianos, Priscilla K., et al.
Publicado: (2021)